RxDoctor Payments Data

Chioma Nwokolo-Nwangwu, MD

Internal Medicine · West Haven, CTNPI 1073674545

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 46 payments — averaging $26.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • EMD Serono, Inc.$125
  • GSK$124
  • E.r. Squibb & Sons, L.L.C.$124
  • Merck$95
  • Boehringer Ingelheim$76
  • plus $447 from 10 others

What the payments were for

  • Food & beverage$1,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$55,114
Medicare patients
58
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$85,253
MounjaroTirzepatide25$35,733
FarxigaDapagliflozin Propanediol20$19,442
WegovySemaglutide12$15,923
EliquisApixaban15$12,537
TradjentaLinagliptin11$5,886
JanuviaSitagliptin Phosphate11$3,192
Lidocaine13$2,307
Rosuvastatin Calcium175$1,811
Nebivolol Hcl14$1,621
Duloxetine Hcl26$1,605
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,486
Atorvastatin Calcium98$1,122
Tolterodine Tartrate ErTolterodine Tartrate12$1,093
Levothyroxine Sodium130$1,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$61$35,73325 claims
AstraZenecaFarxiga$250$19,44220 claims
Boehringer IngelheimTradjenta$76$5,88611 claims
MerckJanuvia$95$3,19211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in West Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →